A. Jacobs

Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain

U. Richarz, J. Devulder, A. Jacobs, 2009, British journal of anaesthesia.

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

C. Rojo, M. Sacristán, L. Sans, 2009, European Psychiatry.

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries

J. Peuskens, J. Olivares, K. Akhras, 2010, Current medical research and opinion.

Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database

T. Lambert, B. Butcher, H. Hustig, 2012, BMC Psychiatry.

Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry

J. Peuskens, J. Olivares, K. Akhras, 2009, Current medical research and opinion.

THE IMPACT OF TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION ON THE BELGIAN HEALTHCARE SYSTEM: RESULTS FROM A BUDGET IMPACT MODEL

L. Annemans, I. Eijgelshoven, G. Bergman, 2012, Acta clinica Belgica.

Reduced polypharmacy in patients enrolled in the electronic schizophrenia adherence registry (E-STAR) and treated with risperidone long-acting injection (RLAI) for 6 months

M. Povey, H. Hustig, J. Olivares, 2007, European psychiatry.

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

J. Peuskens, T. Lambert, C. Kozma, 2011, Annals of general psychiatry.